

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM675254

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
IPD Analytics, LLC		09/17/2021	Limited Liability Company: FLORIDA
Intellectual Property Development, Inc.		09/17/2021	Corporation: FLORIDA
RECEIVING PARTY DATA			
Name:	JPMorgan Chase Bank, N.A.		
Street Address:	237 Park Avenue, 6th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10017		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Serial Number:	90211197	IPD ANALYTICS	
Serial Number:	90004429	BUDGET IMPACT POWERED BY IPD ANALYTICS	
Serial Number:	88595214	IPD ANALYTICS	
Serial Number:	88595841	MARKET & FINANCIAL INSIGHTS POWERED BY I	
Serial Number:	86118291	IPD ANALYTICS	
Serial Number:	85535880	IPDANALYTICS	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	800-494-5225		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	JAY DASILVA		
Address Line 1:	1025 CONNECTICUT AVE., NW, STE. 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	WASHINGTON, D.C. 20036		
ATTORNEY DOCKET NUMBER:	1476799		

OP \$165.00 90211197

NAME OF SUBMITTER:	Andrew Nash
SIGNATURE:	/Andrew Nash/
DATE SIGNED:	09/17/2021

Total Attachments: 41

source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page1.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page2.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page3.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page4.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page5.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page6.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page7.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page8.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page9.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page10.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page11.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page12.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page13.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page14.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page15.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page16.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page17.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page18.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page19.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page20.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page21.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page22.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page23.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page24.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page25.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page26.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page27.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page28.tif

source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page29.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page30.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page31.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page32.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page33.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page34.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page35.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page36.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page37.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page38.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page39.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page40.tif
source=JPM_IPD Analytics - Intellectual Property Security Agreement (9.2021) (EXECUTION VERSION)#page41.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (“Agreement”) is entered into as of September 17, 2021, by and among JPMORGAN CHASE BANK, N.A., in its capacity as administrative agent (the “Administrative Agent”) for the lenders party to the Credit Agreement referred to below, IPD ANALYTICS, LLC, a Florida limited liability company (the “Borrower”), and INTELLECTUAL PROPERTY DEVELOPMENT, INC., a Florida corporation (together with the Borrower, each, a “Grantor” and collectively, the “Grantors”).

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to the Borrower (the “Loans”), in the amounts and manner set forth in that certain Credit Agreement by and among the Administrative Agent, the Lenders party thereto, the Grantors and the other Loan Parties party thereto, dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, collectively, the “Credit Agreement”). The Lenders are willing to make the Loans to the Borrower, but only upon the condition, among others, that each Grantor shall grant to the Administrative Agent a security interest in the Collateral, including certain Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of such Grantor under the Credit Agreement.

B. Pursuant to the terms of the Pledge and Security Agreement, dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the “Security Agreement”; capitalized terms used herein are used as defined in the Credit Agreement), by and among the Administrative Agent and the Grantors, each Grantor has granted to the Administrative Agent a security interest in all of such Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, each Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. Each Grantor grants and pledges to the Administrative Agent a security interest in all of such Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to such Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same,

including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. The parties hereto authorize and request that the Commissioner of Patents, the Commissioner for Trademarks and the Register of Copyrights of the United States record this security interest in the Intellectual Property Collateral.

3. Authorization. Each Grantor hereby authorizes the Administrative Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which such Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Security Agreement, which is hereby incorporated by reference. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Administrative Agent with respect to the Intellectual Property Collateral are as provided by the Credit Agreement, Security Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Balance of Page Intentionally Left Blank]

ADMINISTRATIVE AGENT:

Address:

JPMorgan Chase Bank, N.A.
237 Park Avenue, 6th Floor
New York, NY 10017
Attention: Ted Karsos
Email: ted.karsos@jpmorgan.com

JPMORGAN CHASE BANK, N.A.

By: 
Name: Eleftherios Karsos
Title: Authorized Officer

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTORS:

Address:

19950 W. Country Club, 7th Floor
Aventura, FL 33180

IPD ANALYTICS, LLC

By: 

Name: Howard B. Krass

Title: CEO

**INTELLECTUAL PROPERTY DEVELOPMENT,
INC.**

By: 

Name: Howard B. Krass

Title: Sole Director

[Signature page to Intellectual Property Security Agreement]

TRADEMARK
REEL: 007425 FRAME: 0037

EXHIBIT A

Copyrights

<u>Description</u>	<u>Registration/Application #</u>	<u>Registration/Application Date</u>
<u>\$4 Billion in Generic Launches to Impact Pharmaceutical Management and Drug Budgets.</u>	<u>TX0008782562</u>	<u>2017</u>
<u>505b2 and Growing Competition Puts the Profitability of Tecfidera ANDAs in Jeopardy.</u>	<u>TX0008812943</u>	<u>2018</u>
<u>Abilify: Bristol-Myers Squibb Appears To Have Advantage in Patent Infringement Litigation.</u>	<u>TX0007388066</u>	<u>2010</u>
<u>ABILIFY (OTSUKA): AN OVERVIEW OF THE PATENT LITIGATION.</u>	<u>TX0008224184</u>	<u>2015</u>
<u>Abilify: Otsuka and Bristol-Myers Have Advantage Heading Into Trial.</u>	<u>TX0007387913</u>	<u>2010</u>
<u>Acne Therapy: Cost-effective Quality Choices and Cost Savings.</u>	<u>TX0008425496</u>	<u>2016</u>
<u>Adamas Pharmaceuticals (ADMS): An Overview Of The Patent Situations For Namenda XR, MDX-8704, And ADS-5102.</u>	<u>TX0007947762</u>	<u>2014</u>
<u>Adderall XR Report (SHPGY, TEVA, IPXL, WPI, Actavis, Sandoz): Adderall XR May Not Face Additional Generic Competition Until 2012 or Later.</u>	<u>TX0007387976</u>	<u>2010</u>
<u>ADVAIR DISKUS GENERIC LAUNCH.</u>	<u>TX0008813242</u>	<u>2018</u>
<u>ADVAIR DISKUS GENERIC LAUNCH FORECAST.</u>	<u>TX0008814473</u>	<u>2019</u>
<u>ADVAIR DISKUS GENERIC LAUNCH FORECAST: Following FDA Delays, Generics Likely to Enter Market in Late 2018 and Beyond.</u>	<u>TX0008812690</u>	<u>2018</u>
<u>Aemcolo (rifamycin)</u>	<u>TX0008816889</u>	<u>2018</u>
<u>AFINITOR/VOTUBIA (EVEROLIMUS) REPORT : NOVEMBER, JUNE, JULY HEARINGS TO IMPACT EUROPEAN GENERIC OUTLOOK.</u>	<u>TX0008784129</u>	<u>2017</u>
<u>Aimovig (Erenumab)</u>	<u>TX0008812713</u>	<u>2018</u>

<u>Ajovy (fremanezumab-vfrm)</u>	<u>TX0008812688</u>	<u>2018</u>
<u>Akamai V. Limelight: Appeal Appears To Threaten Limelight Trial Victory.</u>	<u>TX0007371726</u>	<u>2010</u>
<u>Akamai v. Limelight: Limelight Has the Advantage Persuading the Supreme Court that it Does Not Infringe Akamai's Patent.</u>	<u>TX0007948122</u>	<u>2014</u>
<u>Akynzeo (fosnetupitant and palonosetron) injection.</u>	<u>TX0008784731</u>	<u>2018</u>
<u>Albuterol Inhalers - SABA Generic Outlook.</u>	<u>TX0008823391</u>	<u>2019</u>
<u>Albuterol Inhalers - SABA Generic Outlook.</u>	<u>TX0008425492</u>	<u>2016</u>
<u>ALIGN (ALGN): ALIGN'S PATENT PORTFOLIO APPEARS UNLIKELY TO DETER COMPETITORS AFTER OCTOBER 2017.</u>	<u>TX0008169140</u>	<u>2015</u>
<u>Align (ALGN) v. ClearCorrect: Approaching Trials Threaten ClearCorrect's Products.</u>	<u>TX0007672964</u>	<u>2013</u>
<u>Align (ALGN) v. ClearCorrect: ITC Lawsuits Threaten ClearCorrect's Products.</u>	<u>TX0007546902</u>	<u>2012</u>
<u>Align Technology (ALGN) v. ClearCorrect: Align Has Early Advantage In Patent Infringement Lawsuit.</u>	<u>TX0007387934</u>	<u>2011</u>
<u>ALIMTA (LLY): HEADING INTO UPCOMING INFRINGEMENT TRIAL, LILLY APPEARS TO HAVE ADVANTAGE ON 2022 PATENT.</u>	<u>TX0008169303</u>	<u>2015</u>
<u>Allegra, Allegra-D 12 Hour, and Allegra-D 24 Hour: An Overview of the Generic Landscape.</u>	<u>TX0007387941</u>	<u>2011</u>
<u>Allegra-D 24 Hour: An In-Depth Look At The Allegra-D 24 Hour Preliminary Injunction Motion.</u>	<u>TX0007388058</u>	<u>2010</u>
<u>Allergic Conjunctivitis: Antihistamine/Mast Cell Stabilizer Patanol Management.</u>	<u>TX0008226785</u>	<u>2015</u>
<u>Amantadine Update- Osmolex ER and Gocovri Parkinson's Disease.</u>	<u>TX0008808090</u>	<u>2018</u>
<u>Amgen (Amjevita) - Humira Biosimilar Settlement with AbbVie What is the impact of this settlement?</u>	<u>TX0008782559</u>	<u>2017</u>
<u>Amitiza (SCMP): An Early Look At The Patent Litigation.</u>	<u>TX0007777032</u>	<u>2013</u>

<u>AMP v. Myriad Genetics (MYGN): Appeals Court Appears Inclined To Overturn District Court Decision.</u>	<u>TX0007423775</u>	<u>2011</u>
<u>AMP v. Myriad Genetics (MYGN): Myriad Appears To Hold Advantage On Overturning All Or At Least Some Of District Court's Invalidity Decision.</u>	<u>TX0007379614</u>	<u>2011</u>
<u>AMP v. Myriad (MYGN): Lawsuit Unlikely to Significantly Impact Myriad's Blocking Position.</u>	<u>TX0007371651</u>	<u>2010</u>
<u>Ampyra (ACOR): An Overview Of Acorda's Patent Protection For Ampyra.</u>	<u>TX0007824324</u>	<u>2013</u>
<u>AMRI01 (Amarin): An Initial Look at the AMRI01 Patent Situation.</u>	<u>TX0007392916</u>	<u>2011</u>
<u>Amrix (Ceph): Patent Office Soon Will Issue New Patent With Improved Protection For Amrix.</u>	<u>TX0007387955</u>	<u>2010</u>
<u>AndexXa (andexanet alfa)</u>	<u>TX0008812693</u>	<u>2018</u>
<u>AndroGel (ABBV): Supreme Court To Consider Whether Reverse-Payment Agreements Violate Anti-Trust Laws.</u>	<u>TX0007720753</u>	<u>2013</u>
<u>AndroGel (ABT, TEVA, BPAX, WPI, PRX): Teva Has Advantage Heading Into Trial, May Launch "At Risk" In 3Q 2012.</u>	<u>TX0007472467</u>	<u>2011</u>
<u>Anemia in Patients with Chronic Kidney Disease: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors.</u>	<u>TX0008784761</u>	<u>2018</u>
<u>Angiomax (MDCO): A Preview Of The Coming Trial Against Hospira.</u>	<u>TX0007824321</u>	<u>2013</u>
<u>Angiomax (MDCO): A Preview Of The Coming Trial Against Mylan.</u>	<u>TX0007948018</u>	<u>2014</u>
<u>Angiomax (MDCO): An Update On The Patent Litigation Over Proposed Generic Angiomax.</u>	<u>TX0007464634</u>	<u>2011</u>
<u>Angiomax Update (MDCO): Solicitor General Elects Not to Appeal Patent Term Extension; Angiomax Unlikely to Face Generic Competition Until June 2015.</u>	<u>TX0007387925</u>	<u>2010</u>
<u>Apple (AAPL) v. HTC: ITC Lawsuits Threaten Each Company's Key Products.</u>	<u>TX0007371730</u>	<u>2010</u>
<u>APPLE ATTACKS ERICSSON'S PATENT ROYALTY STRUCTURE; QUALCOMM AND</u>	<u>TX0008224452</u>	<u>2015</u>

<u>OTHERS WITH SIMILAR ROYALTY STRUCTURES FACE COLLATERAL RISK.</u>		
<u>Apple v. Motorola (AAPL V. GOOG, MSD): Appeals Court Likely Will Give Parties Another Chance For Remedies.</u>	<u>TX0007947719</u>	<u>2014</u>
<u>Apple v. Motorola (AAPL V. GOOG, MSD): Appeals Court Likely Will Give Parties Another Chance For Remedies.</u>	<u>TX0007947708</u>	<u>2014</u>
<u>Apple v. Motorola Mobility (AAPL v. GOOG): Appeals Court To Consider Whether To Revive Apple's Request For Court-Determined FRAND Rate.</u>	<u>TX0007947706</u>	<u>2014</u>
<u>Asparlas (calaspargase pegol-mknl)</u>	<u>TX0008801790</u>	<u>2018</u>
<u>Asthma/COPD: Authorized Generic Albuterol Competition Launched.</u>	<u>TX0008807295</u>	<u>2019</u>
<u>AstraZeneca's 9th inning attempt to keep additional Crestor generics off the market.</u>	<u>TX0008388243</u>	<u>2016</u>
<u>Astrazeneca's Brillinta Likely Protected From Generic Competition Until 2024.</u>	<u>TX0007947766</u>	<u>2014</u>
<u>Attention Deficit Hyperactivity Disorder (ADHD): Drug Management Strategy.</u>	<u>TX0008412332</u>	<u>2017</u>
<u>Atypical Antipsychotics (2nd Generation) Product Lifecycle Management.</u>	<u>TX0008394075</u>	<u>2016</u>
<u>Atypical Antipsychotics (2nd Generation) Product Lifecycle Management.</u>	<u>TX0008226838</u>	<u>2015</u>
<u>Aubagio (SNY): Genzyme's Aubagio Likely Protected From Generic Competition Until 2026.</u>	<u>TX0007947764</u>	<u>2014</u>
<u>Avonex (BIIB): An In-Depth Look at the 2026 Avonex Patent.</u>	<u>TX0007388008</u>	<u>2010</u>
<u>AVONEX-REBIF (INTERFERON-BETA) REPORT: POST-TRIAL BRIEFING HIGHLIGHTS DEFICIENCIES WITH JURY VERDICT THAT MAY CAUSE BIOGEN TO PREVAIL.</u>	<u>TX0008812681</u>	<u>2018</u>
<u>Azedra (iobenguane I-131)</u>	<u>TX0008789530</u>	<u>2018</u>
<u>Azilect (TEVA): Teva Appears To Have Advantage In Litigation Over Proposed Generic Versions Of Azilect.</u>	<u>TX0007544163</u>	<u>2012</u>
<u>Basal Insulin Outlook.</u>	<u>TX0008812715</u>	<u>2019</u>

<u>Becton, Dickinson v. Insulet (BDX, PODD) Update: An Early Look.</u>	<u>TX0007379612</u>	<u>2010</u>
<u>BENDEKA & TREANDA (EGRX, TEVA): FDA CONSIDERS NEXT STEPS IN BENDAMUSTINE EXCLUSIVITY FIGHT.</u>	<u>TX0008808653</u>	<u>2019</u>
<u>Biktavey (bictegravir/emtricitabine/tenofovir alafenamide) Drug Information.</u>	<u>TX0008789570</u>	<u>2018</u>
<u>BIODELIVERY SCIENCES INT'L (BDSI): AN OVERVIEW OF THE PATENT SITUATIONS FOR ITS PRODUCTS.</u>	<u>TX0007987553</u>	<u>2014</u>
<u>Biologics in Severe Asthma.</u>	<u>TX0008388262</u>	<u>2016</u>
<u>BOSTON SCIENTIFIC (BSX) V. EDWARDS (EW): AN EARLY LOOK AT THE LAWSUITS.</u>	<u>TX0008357278</u>	<u>2016</u>
<u>Botulinum Toxin Management.</u>	<u>TX0008412314</u>	<u>2017</u>
<u>Broadcasters v. Aereo: Supreme Court Likely to be Skeptical of Aereo; Decision May Create Risk for Cloud Services.</u>	<u>TX0007948124</u>	<u>2014</u>
<u>Bryhali Lotion 0.01% (halobetasol propionate)</u>	<u>TX0008793346</u>	<u>2018</u>
<u>Busy December at FDA.</u>	<u>TX0008785276</u>	<u>2017</u>
<u>Bystolic (FRX): Bystolic May Face Generic Competition By 2015 Or Sooner.</u>	<u>TX0007595633</u>	<u>2012</u>
<u>C. Difficile product in development.</u>	<u>TX0008414317</u>	<u>2017</u>
<u>C.R. Bard (BCR) v. W.L. Gore: Appeal Appears to Threaten Bard's Trial Victory.</u>	<u>TX0007416038</u>	<u>2011</u>
<u>C.R. Bard (BCR) v. W.L. Gore: Appeals Court Likely Will Affirm Bard's \$520M Trial Victory.</u>	<u>TX0007387931</u>	<u>2011</u>
<u>Cablivi (caplacizumab-yhdp)</u>	<u>TX0008814458</u>	<u>2019</u>
<u>Cancer Vaccines.</u>	<u>TX0008782554</u>	<u>2017</u>
<u>CARDIAQ (EW) V. NEOVASC (NVCN): AN EARLY LOOK AT TRANSCATHETER MITRAL VALVE IMPLANT PATENT DISPUTE.</u>	<u>TX0008224458</u>	<u>2016</u>
<u>Cardiovascular: Antiplatelet Management.</u>	<u>TX0008387975</u>	<u>2016</u>

<u>CARNEGIE MELLON UNIVERSITY v. MARVELL: FEDERAL CIRCUIT LIKELY WILL OVERTURN DAMAGE AWARD.</u>	<u>TX0008114922</u>	<u>2015</u>
<u>CGRP FORECAST: Early Success for Amgen's Aimovig, But Intense Formulary Access Competition Between Similar Products Will Level the Playing Field.</u>	<u>TX0008812814</u>	<u>2018</u>
<u>Chemotherapy Induced Nausea and Vomiting Medications: Opportunities for cost savings.</u>	<u>TX0008414264</u>	<u>2017</u>
<u>CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL LANDSCAPE.</u>	<u>TX0008214461</u>	<u>2015</u>
<u>Chimeric Antigen Receptor (CAR) T-cell Therapy.</u>	<u>TX0008414276</u>	<u>2017</u>
<u>CHINA ANTITRUST INVESTIGATION THREATENS QUALCOMM PATENT LICENSING MODEL.</u>	<u>TX0008224183</u>	<u>2015</u>
<u>Chronic Idiopathic Constipation, Irritable Bowel Syndrome with constipation, and Opioid Induced Constipation: Utilization and Management.</u>	<u>TX0008784737</u>	<u>2018</u>
<u>CISCO (CSCO) v. ARISTA (ANET): LAWSUITS MAY MATERIALLY THREATEN ARISTA.</u>	<u>TX0008018433</u>	<u>2014</u>
<u>CNS NEUROSTEROIDS: A LOOK AT THE PATENT PORTFOLIOS OF SAGE AND MARINUS.</u>	<u>TX0008784767</u>	<u>2018</u>
<u>Colony Stimulating Factor Management.</u>	<u>TX0008226843</u>	<u>2015</u>
<u>Combigan (AGN): Allergan Appears To Have Advantage In Upcoming Trial.</u>	<u>TX0007427942</u>	<u>2011</u>
<u>Combivir: Teva May Have Opportunity To Launch At Risk in May 2010.</u>	<u>TX0007388018</u>	<u>2010</u>
<u>Competitive Landscape Analysis: Achillion (ACHN) HCV Pipeline.</u>	<u>TX0007948017</u>	<u>2014</u>
<u>COMPETITIVE LANDSCAPE ANALYSIS: ACHILLION'S HCV PIPELINE.</u>	<u>TX0008224456</u>	<u>2016</u>
<u>Competitive Landscape Analysis: ADHD Therapies.</u>	<u>TX0007577193</u>	<u>2012</u>
<u>COMPETITIVE LANDSCAPE ANALYSIS: ANDROGEN RECEPTOR ANTAGONISTS AND ANDROGEN SYNTHESIS INHIBITORS.</u>	<u>TX0008357016</u>	<u>2016</u>

<u>COMPETITIVE LANDSCAPE ANALYSIS: CD38 ANTIBODIES.</u>	<u>TX0008356760</u>	<u>2016</u>
<u>Competitive Landscape Analysis: Diabetes Care Devices.</u>	<u>TX0007948152</u>	<u>2014</u>
<u>Competitive Landscape Analysis: Diabetes Therapies.</u>	<u>TX0007482299</u>	<u>2011</u>
<u>Competitive Landscape Analysis: Lung Cancer Therapies.</u>	<u>TX0007544113</u>	<u>2012</u>
<u>Competitive Landscape Analysis: Obesity Therapies.</u>	<u>TX0007595635</u>	<u>2012</u>
<u>COMPETITIVE LANDSCAPE ANALYSIS: PARP INHIBITORS.</u>	<u>TX0008357026</u>	<u>2016</u>
<u>Competitive Landscape Analysis: PCSK9 Antibodies.</u>	<u>TX0007824329</u>	<u>2013</u>
<u>Competitive Landscape Analysis (PD-1 & PD-L1 Antibodies): BMS Patents May Cover Three Competing PD-1 Products.</u>	<u>TX0007948020</u>	<u>2014</u>
<u>COMPETITIVE LANDSCAPE ANALYSIS: PD-L1 ANTIBODIES.</u>	<u>TX0008357046</u>	<u>2016</u>
<u>COMPETITIVE LANDSCAPE ANALYSIS: PD-L1 ANTIBODIES.</u>	<u>TX0008425499</u>	<u>2016</u>
<u>Competitive Landscape Analysis: Rheumatoid Arthritis Therapies.</u>	<u>TX0007464627</u>	<u>2011</u>
<u>Competitors Unlikely to Topple Restasis as the Dry Eye Market Leader.</u>	<u>TX0008814099</u>	<u>2018</u>
<u>Cook Medical v. Endologix (ELGX): Endologix Unlikely To Face Injunction.</u>	<u>TX0007379893</u>	<u>2010</u>
<u>COPAXONE 40 MG/ML (TEVA): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008357313</u>	<u>2016</u>
<u>COPAXONE 40 MG/ML (TEVA): AN EARLY LOOK AT THE PETITIONS FOR IPR PROCEEDINGS.</u>	<u>TX0008114789</u>	<u>2015</u>
<u>Copaxone Generics Update.</u>	<u>TX0008782565</u>	<u>2017</u>
<u>Copaxone Report (TEVA, MNTA, NVS): Teva Appears to Have Advantage Heading Into Tomorrow's Markman Hearing.</u>	<u>TX0007388055</u>	<u>2010</u>
<u>Copiktra (duvelisib)</u>	<u>TX0008812898</u>	<u>2018</u>

<u>Crestor (AZN): Parties Await Trial Decision on 2016 Patent; Method-of-Use Patents May Provide Additional Protection against Generic Competition.</u>	<u>TX0007388067</u>	<u>2010</u>
<u>Crysvita (Burosumab)</u>	<u>TX0008784725</u>	<u>2018</u>
<u>Crysvita (burosumab-twza)</u>	<u>TX0008814166</u>	<u>2018</u>
<u>Cubicin (CBST v. HSP): Cubist Appears To Have Advantage Heading Into Markman Hearing.</u>	<u>TX0007720758</u>	<u>2013</u>
<u>Cubicin (CBST v. HSP): Heading Into Trial, Cubist Has Advantage On 2019 And 2020 Patents.</u>	<u>TX0007947767</u>	<u>2014</u>
<u>Cubicin (CBST V. TEVA): Cubist Appears to Have Advantage in Defending 2019 Dosing Patents Against Teva's New Allegations of Inequitable Conduct.</u>	<u>TX0007388039</u>	<u>2010</u>
<u>Cubicin (CBST v. TEVA): Heading Into Trial, Cubist Appears To Have Advantage.</u>	<u>TX0007387991</u>	<u>2011</u>
<u>Cubicin: Cubist Appears To Have Advantage Heading Into Markman Hearing.</u>	<u>TX0007388049</u>	<u>2010</u>
<u>Current Therapies for heart failure with reduced ejection fraction (HFrEF)</u>	<u>TX0008425501</u>	<u>2017</u>
<u>Cystic Fibrosis: Products and Trends.</u>	<u>TX0008425491</u>	<u>2017</u>
<u>DALIRESP: AN EARLY LOOK AT THE LITIGATION.</u>	<u>TX0008169142</u>	<u>2015</u>
<u>DAPAGLIFLOZIN: UNDERSTANDING ASTRAZENECA'S AND PROSPECTIVE ANDA FILERS? DAPAGLIFLOZIN PATENTS.</u>	<u>TX0008425506</u>	<u>2017</u>
<u>Daurismo (glasdegib)</u>	<u>TX0008793382</u>	<u>2018</u>
<u>Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) Pifeltro (doravirine)</u>	<u>TX0008812804</u>	<u>2018</u>
<u>Dermatology Management: Eucrisa for Eczema/Atopic Dermatitis.</u>	<u>TX0008425476</u>	<u>2016</u>
<u>Dexilant (Takeda v. Par): Takeda Appears To Have Advantage On 2020 Patents Following Markman Ruling.</u>	<u>TX0007544090</u>	<u>2012</u>

<u>Diabetes: GLP1 Class Management.</u>	<u>TX0008784790</u>	<u>2018</u>
<u>Diabetes: Long acting insulin products.</u>	<u>TX0008412320</u>	<u>2016</u>
<u>Diabetes: SGLT2 Class Management.</u>	<u>TX0008784756</u>	<u>2018</u>
<u>Diacomit (stiripentol)</u>	<u>TX0008812845</u>	<u>2018</u>
<u>Direct Oral Anticoagulants.</u>	<u>TX0008787258</u>	<u>2017</u>
<u>Direct Oral Anticoagulants.</u>	<u>TX0008787254</u>	<u>2017</u>
<u>Doptelet (avatrombopag)</u>	<u>TX0008812683</u>	<u>2018</u>
<u>Drisapersen (Prosensa) And Eteplirsen (Sarepta): An Overview Of The Patent Situation.</u>	<u>TX0007777010</u>	<u>2013</u>
<u>Drug Trend Impact.</u>	<u>TX0008785619</u>	<u>2017</u>
<u>Drug Trend Impact: Summer 2018.</u>	<u>TX0008810408</u>	<u>2018</u>
<u>Dry Eye Disease (DED): Drug Management Strategy.</u>	<u>TX0008783778</u>	<u>2017</u>
<u>Duchenne Muscular Dystrophy (DMD)</u>	<u>TX0008226846</u>	<u>2015</u>
<u>Dupixent (dupilumab)</u>	<u>TX0008812846</u>	<u>2018</u>
<u>DUPIXENT (DUPILUMAB) REPORT: AN OVERVIEW OF THE AMGEN-REGENERON PATENT DISPUTES.</u>	<u>TX0008412343</u>	<u>2017</u>
<u>EARLIER.....GENERIC/BIOSIMILAR COMPETITION POSSIBLE DUE TO READ- THROUGH FROM TAMIFLU AND REMICADE RULINGS.</u>	<u>TX0008357048</u>	<u>2016</u>
<u>EARLY IPR STATISTICS IN THE PHARMACEUTICAL SECTOR.</u>	<u>TX0008224144</u>	<u>2015</u>
<u>EARLY LOOK AT NEW ORAL TESTOSTERONES.</u>	<u>TX0008425464</u>	<u>2017</u>
<u>Edwards & Medtronic (EW, MDT): Tavi Patent Landscape.</u>	<u>TX0007846167</u>	<u>2013</u>
<u>Edwards Lifesciences v. Medtronic (EW v. MDT): Transcatheter Heart Valve Appeal and Early Stage Litigation Overview.</u>	<u>TX0007472465</u>	<u>2011</u>

<u>Effient (LLY): An Overview Of Eli Lilly's Patent Portfolio For Effient.</u>	<u>TX0007824332</u>	<u>2013</u>
<u>Elzonris (tagraxofusp-erzs)</u>	<u>TX0008802445</u>	<u>2019</u>
<u>Embeda (KG): Early Look at Litigation: Summary Judgment Hearing Tomorrow.</u>	<u>TX0007387947</u>	<u>2010</u>
<u>Emerging Treatments for Peanut Allergy.</u>	<u>TX0008807290</u>	<u>2019</u>
<u>Emflaza (deflazacort)/Marathon: Summary of issues and management in patients with DMD.</u>	<u>TX0008425486</u>	<u>2017</u>
<u>Emgality (galcanezumab-gnlm)</u>	<u>TX0008812691</u>	<u>2018</u>
<u>Enablex (WCRX TEVA WPI): An Early Look At The Generic Enablex Patent Litigation.</u>	<u>TX0007387922</u>	<u>2010</u>
<u>Enbrel (AMGN, PFE): An Analysis of the 2028 Enbrel Patent.</u>	<u>TX0007482294</u>	<u>2011</u>
<u>ENBREL (AMGN, PFE): AN UPDATED ANALYSIS OF THE 2028 AND 2029 PATENTS.</u>	<u>TX0008224449</u>	<u>2016</u>
<u>Enbrel European Biosimilar Quickly Reducing Price Inflammation in EU.</u>	<u>TX0008388260</u>	<u>2016</u>
<u>Enzo (ENZ): An Early Look At Enzo's Recent Patent Lawsuits.</u>	<u>TX0007777035</u>	<u>2013</u>
<u>Epidiolex (cannabidiol/CBD)</u>	<u>TX0008812700</u>	<u>2018</u>
<u>Epinephrine Injection: Expiration date and other updates.</u>	<u>TX0008414299</u>	<u>2017</u>
<u>Epinephrine Subcutaneous Injection for Anaphylactic reactions:.</u>	<u>TX0008425482</u>	<u>2017</u>
<u>EpiPen (MYL, PFE v. TEVA, AIS): King Appears To Have The Advantage Heading Into Markman Hearing.</u>	<u>TX0007456411</u>	<u>2011</u>
<u>Erleada (apalutamide)</u>	<u>TX0008813850</u>	<u>2018</u>
<u>Estrace Cream Generic Launch Forecast.</u>	<u>TX0008814183</u>	<u>2018</u>
<u>ESTRACE CREAM GENERIC LAUNCH FORECAST UPDATE: Increased Competition Likely Will Continue to Accelerate Generic Price Decrease.</u>	<u>TX0008812822</u>	<u>2018</u>
<u>Evaluating Potential Generic Opportunities : How clinical, regulatory, legislative, and</u>	<u>TX0008785277</u>	<u>2017</u>

<u>formulary changes will define the best and worst candidates.</u>		
<u>Evista (LLY TEVA): Appeals Court Likely Will Affirm Decision Excluding Generic Competition Until 2014.</u>	<u>TX0007387892</u>	<u>2010</u>
<u>Exelon Patch (NVS): Novartis v. Par Trial Begins Tomorrow.</u>	<u>TX0007947758</u>	<u>2014</u>
<u>Exelon Patch (NVS, WPI): Novartis Faces Threat Of Generic Competition In 2014.</u>	<u>TX0007544107</u>	<u>2012</u>
<u>Fanapt: An Early Look At The Patent Litigation.</u>	<u>TX0007953036</u>	<u>2014</u>
<u>FASLODEX GENERIC FORECAST.</u>	<u>TX0008812714</u>	<u>2019</u>
<u>FDA ADVISORY COMMITTEE VOTES 14-2 IN FAVOR OF RISK-BENEFIT FOR INTRANASAL ESKETAMINE FOR TREATMENT-RESISTANT DEPRESSION.</u>	<u>TX0008814448</u>	<u>2019</u>
<u>FDA Advisory Meeting Vote Split on Sotagliflozin Oral Tablets for Type 1 Diabetes.</u>	<u>TX0008814476</u>	<u>2019</u>
<u>FDA Approves First Generic Version of Lialda.</u>	<u>TX0008781173</u>	<u>2017</u>
<u>Fentora (CEPH v. WPI): Trial Decision Likely Will Favor Watson, but Citizen Petitions May Delay Approval.</u>	<u>TX0007387905</u>	<u>2010</u>
<u>Financial Forecast: Giapreza Utilization Likely Modest.</u>	<u>TX0008814058</u>	<u>2018</u>
<u>Firdapse (amifampridine)</u>	<u>TX0008794302</u>	<u>2018</u>
<u>Fulphila: Pegfilgrastim Biosimilar.</u>	<u>TX0008814174</u>	<u>2018</u>
<u>Future Budget Buster Dupilumab for Atopic Dermatitis.</u>	<u>TX0008388259</u>	<u>2016</u>
<u>Galafold (migalastat)</u>	<u>TX0008812842</u>	<u>2018</u>
<u>Gamifant (emapalumab-1zsg)</u>	<u>TX0008793355</u>	<u>2018</u>
<u>Gemalto (GTO) v. Samsung, HTC, Google (GOOG): Appeals Court Appears Inclined To Affirm Gemalto Loss.</u>	<u>TX0007947703</u>	<u>2014</u>
<u>Gemzar (LLY v. TEVA): District Court Most Likely Will Uphold 2010 Patent But Strike Down 2013 Patent.</u>	<u>TX0007388072</u>	<u>2010</u>

<u>Gen-Probe (GPRO) V. Becton Dickinson (BDX): An Early Look at the BD Viper and BD ProbeTec Lawsuit.</u>	<u>TX0007371652</u>	<u>2010</u>
<u>Gene Therapies in Clinical Development.</u>	<u>TX0008782555</u>	<u>2017</u>
<u>GENE THERAPIES IN CLINICAL DEVELOPMENT: FORMULARY PLANNING AND MANAGEMENT.</u>	<u>TX0008793423</u>	<u>2018</u>
<u>Generic and Biosimilar Landscape Analysis: Multiple Sclerosis Monotherapies.</u>	<u>TX0007416036</u>	<u>2011</u>
<u>Generic Cubicin (daptomycin) should become available in June 2016.</u>	<u>TX0008388250</u>	<u>2016</u>
<u>Generic Landscape Analysis: Angiotensin Receptor Blockers.</u>	<u>TX0007443242</u>	<u>2011</u>
<u>Generic Landscape Analysis: Erectile Dysfunction Drugs.</u>	<u>TX0007387998</u>	<u>2011</u>
<u>Giapreza (angiotensin II)/La Jolla: Therapy for use in hypotension due to distributive shock.</u>	<u>TX0008784748</u>	<u>2018</u>
<u>Giapreza Net Sales Exceed IPD Analytics Estimate but Underperform Analyst Consensus.</u>	<u>TX0008814471</u>	<u>2019</u>
<u>Gilead's Hepatitis C Authorized Generics.</u>	<u>TX0008812653</u>	<u>2018</u>
<u>Gilenya (NVS): An Overview Of Novartis's Patent Portfolio.</u>	<u>TX0007824331</u>	<u>2013</u>
<u>GLAUCOMA FINANCIAL FORECAST: MIXED MARKET POTENTIAL FOR NEW ENTRANTS.</u>	<u>TX0008812620</u>	<u>2018</u>
<u>GLEEVEC (NVS): UNDERSTANDING THE TIMING FOR GENERIC COMPETITION.</u>	<u>TX0008224439</u>	<u>2015</u>
<u>Gleevec (NVS): Understanding The Timing For Potential Generic Competition.</u>	<u>TX0007622299</u>	<u>2012</u>
<u>Glucagon-like peptide-1 (GLP-1) Agonists : Market disruption may provide new formulary management opportunities.</u>	<u>TX0008784085</u>	<u>2017</u>
<u>Glumetza: Generic Outlook.</u>	<u>TX0008412317</u>	<u>2016</u>
<u>Glycoprotein IIB/IIIA Receptor Inhibitors: Use in Percutaneous Coronary Interventions.</u>	<u>TX0008812812</u>	<u>2018</u>
<u>GOPRO PATENTS MAY NOT DETER APPLE FROM ENTERING THE SPORTS CAMERA MARKET.</u>	<u>TX0008224149</u>	<u>2015</u>

<u>Gralise (DEPO): An Early Look At The Patent Litigation.</u>	<u>TX0007606263</u>	<u>2012</u>
<u>Gralise (DEPO): Heading Into Trial. Depomed Appears To Have Advantage.</u>	<u>TX0007947757</u>	<u>2014</u>
<u>H.P. Acthar Gel (repository corticotropin injection)</u>	<u>TX0008425503</u>	<u>2017</u>
<u>Haemonetics v. Fenwal: Appeals Court Likely Will Overturn Trial Decision In Favor of Haemonetics.</u>	<u>TX0007371649</u>	<u>2010</u>
<u>Haemonetics v. Fenwal: appeals court likely will overturn trial decision in favor of Haemonetics & 162 other titles.</u>	<u>V9916D905</u>	<u>2014</u>
<u>Hemlibra.</u>	<u>TX0008793410</u>	<u>2018</u>
<u>Hemophilia- Time for Management.</u>	<u>TX0008357281</u>	<u>2016</u>
<u>Hemophilia ? Update on Treatment Management.</u>	<u>TX0008812716</u>	<u>2019</u>
<u>Hepatitis C: Drug Management Outlook.</u>	<u>TX0008387969</u>	<u>2016</u>
<u>HEREDITARY TRANSTHYRETIN-RELATED (hATTR) AMYLOIDOSIS: Onpatro Likely Will Lead the Market, Followed Closely by Tegsedi.</u>	<u>TX0008817285</u>	<u>2018</u>
<u>Hertlioz (VND4): An Overview Of Vanda's Patent Portfolio.</u>	<u>TX0007846279</u>	<u>2013</u>
<u>HIV LANDSCAPE.</u>	<u>TX0008226840</u>	<u>2015</u>
<u>HUMIRA (ADALIMUMAB): AN ANALYSIS OF ABBVIE'S NEW FORMULATION PATENTS.</u>	<u>TX0008169138</u>	<u>2015</u>
<u>HUMIRA (ADALIMUMAB): AN ANALYSIS OF HOW A NEW HUMIRA FORMULATION COULD AFFECT THE BIOSIMILAR LANDSCAPE.</u>	<u>TX0008224147</u>	<u>2015</u>
<u>HUMIRA (ADALIMUMAB) GLOBAL INSIGHTS REPORT: ABBVIE SUBMITS RESPONSE IN EUROPEAN 2022 DOSING PATENT OPPOSITION.</u>	<u>TX0008110949</u>	<u>2015</u>
<u>Humira Biosimilar in 2018?</u>	<u>TX0008414305</u>	<u>2017</u>
<u>Humira Management: Formulation Concentration Change.</u>	<u>TX0008425474</u>	<u>2017</u>

<u>Hyperhidrosis ? Outlook for Dermira's Obrexza Potential for strong utilization due to lack of alternatives.</u>	<u>TX0008793434</u>	<u>2018</u>
<u>Hyperion Therapeutics (HPTX): An Overview Of The Patent Situations For Ravicti, Buphenyl, And DiaPep277.</u>	<u>TX0007948012</u>	<u>2014</u>
<u>Hypertension: Benicar Update.</u>	<u>TX0008414274</u>	<u>2016</u>
<u>I2 v. Oracle: I2 Holds Overall Advantage In Patent Duel With Oracle.</u>	<u>TX0007371724</u>	<u>2010</u>
<u>ICER FINDINGS LIKELY TO BOOST UPTAKE OF XTANDI AND ERLEADA IN NON-METASTATIC DISEASE AS PAYERS LOOK TO MORE AGGRESSIVELY MANAGE THE CLASS Midwest Comparative Effectiveness Public Advisory Council (CEPAC) Public Hearing on Prostate Cancer Drugs Reviewed: Z</u>	<u>TX0008812827</u>	<u>2018</u>
<u>ICER MODEL FINDS MARGINAL BENEFIT AND LACK OF LONG TERM COST-EFFECTIVENESS FOR EXTENDED-RELEASE MEDICATIONS FOR ADDICTION TREATMENT (MAT) IN PATIENTS WITH OPIOID DISORDER.</u>	<u>TX0008816885</u>	<u>2018</u>
<u>ICER MODEL LIKELY UNDERESTIMATES FINANCIAL IMPACT TO PAYERS FOR ONPATTRO AND INOTERSEN MIDWEST COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (CEPAC) PUBLIC HEARING ON HEREDITARY TRANSTHYRETIN-RELATED AMYLOIDOSIS Drugs Reviewed: Onpattro (Alynfam) and</u>	<u>TX0008812833</u>	<u>2018</u>
<u>ICER Public Meeting: A Review of Biologic Therapies for the Treatment of Moderate to Severe Uncontrolled Asthma.</u>	<u>TX0008802451</u>	<u>2018</u>
<u>ICER'S CALIFORNIA TECHNOLOGY ASSESSMENT FORUM (CTAF) PUBLIC HEARING ON THERAPIES FOR THE PREVENTION OF HEREDITARY ANGIOEDEMA: Comparative clinical effectiveness and value of long-term prophylaxis for hereditary angioedema (HAE) with lanadelumab and C1 inh</u>	<u>TX0008793421</u>	<u>2018</u>

<u>ICS LABA - Advair Diskus Generic Outlook.</u>	<u>TX0008425494</u>	<u>2017</u>
<u>IDELVION : A LOOK AT THE BIOVERATIV V. CSL BEHRING PATENT FIGHT.</u>	<u>TX0008784102</u>	<u>2017</u>
<u>ILLUMINA AND QIAGEN DISPUTE.</u>	<u>TX0008357279</u>	<u>2016</u>
<u>Illumina And Sequenom: Parties Grapple For Advantage.</u>	<u>TX0007948145</u>	<u>2014</u>
<u>Illumina v. Complete Genomics (ILMN GNOM): An Early Look At The Lawsuit.</u>	<u>TX0007427940</u>	<u>2011</u>
<u>Illumina v. Life: Appeals Court Likely Will Affirm January 2009 Jury Verdict in Favor of Life.</u>	<u>TX0007379606</u>	<u>2010</u>
<u>Ilumya (tildrakizumab-asmn): Adult Plaque Psoriasis.</u>	<u>TX0008812665</u>	<u>2018</u>
<u>IMMERSION v. APPLE: AN EARLY LOOK AT IMMERSION'S ITC LAWSUIT.</u>	<u>TX0008387729</u>	<u>2016</u>
<u>Immune Globulin Management.</u>	<u>TX0008388254</u>	<u>2016</u>
<u>Immune Globulin Therapy Management.</u>	<u>TX0008812813</u>	<u>2018</u>
<u>Impact of An Authorized Generic in DPP4 inhibitor class?</u>	<u>TX0008388252</u>	<u>2016</u>
<u>Impact Of Mayo v. Prometheus On Method-Of-Use Patents In The Pharmaceutical Sector.</u>	<u>TX0007559171</u>	<u>2012</u>
<u>IMPAX'S RYTARY LIKELY PROTECTED FROM GENERIC COMPETITION UNTIL AT LEAST 2018.</u>	<u>TX0008169325</u>	<u>2015</u>
<u>Inbrija (levodopa inhalation powder)</u>	<u>TX0008801754</u>	<u>2018</u>
<u>INCB18424 (INCY): Composition-of-Matter Patent Appears to Protect INCB18424 Through At Least December 2027.</u>	<u>TX0007388027</u>	<u>2010</u>
<u>Infertility: Class Overview.</u>	<u>TX0008784122</u>	<u>2017</u>
<u>Inflammatory Conditions: Drug Management Strategy.</u>	<u>TX0008782563</u>	<u>2017</u>
<u>Inflammatory Conditions: Drug Management Strategy.</u>	<u>TX0008349107</u>	<u>2016</u>
<u>Inflectra (infliximab-dyyb): Remicade Biosimilar.</u>	<u>TX0008388240</u>	<u>2016</u>

<u>INOMAX (MNK): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008425497</u>	<u>2017</u>
<u>INOMAX (MNK): AN EARLY LOOK AT THE PETITIONS REQUESTING IPR PROCEEDINGS.</u>	<u>TX0008114913</u>	<u>2015</u>
<u>Intel v. Nvidia (NVDA): Nvidia Unlikely to Obtain Further Patent Payments from Intel after January 2016.</u>	<u>TX0007948138</u>	<u>2014</u>
<u>Inter Partes Review (IPR) and 180 Day Exclusivity.</u>	<u>TX0008226869</u>	<u>2015</u>
<u>INTERDIGITAL (IDCC) v. NOKIA AND ZTE: INTERDIGITAL AT DISADVANTAGE REVERSING ADVERSE ITC DECISION ON APPEAL.</u>	<u>TX0008018435</u>	<u>2014</u>
<u>InterDigital (IDCC) v. Nokia, Huawei, and ZTE: InterDigital Likely to Suffer Strategic Loss at ITC.</u>	<u>TX0007846290</u>	<u>2013</u>
<u>InterDigital (IDCC) v. Samsung, Nokia, and ZTE: InterDigital Likely To Suffer Strategic Loss At ITC.</u>	<u>TX0007948102</u>	<u>2014</u>
<u>INTERNATIONAL PRICING INDEX PAYMENT MODEL INITIATIVE.</u>	<u>TX0008793392</u>	<u>2018</u>
<u>Intuniv (Shire): Intuniv Faces Threat of Generic Competition in Q4 2012.</u>	<u>TX0007482306</u>	<u>2011</u>
<u>Invanz ? Carbapenem Update.</u>	<u>TX0008782556</u>	<u>2017</u>
<u>INVANZ (ERTAPENAM) GENERIC LAUNCH FORECAST: Brand Expected to Maintain a Sizeable Portion of the Market Until Additional Generic Entrants Launch.</u>	<u>TX0008812594</u>	<u>2018</u>
<u>IPD Analytics Drug Strategy: Bortezomib (Velcade)</u>	<u>TX0008388255</u>	<u>2016</u>
<u>IPD Drug Alert: FDA Approves First Generic Version of Lialda.</u>	<u>TX0008412334</u>	<u>2017</u>
<u>IPD Drug Strategy Review ICS/LABA Class Strategy: Advair Generics.</u>	<u>TX0008356869</u>	<u>2016</u>
<u>IPD Rx Insights: Future Budget Buster Dupilumab for Atopic Dermatitis.</u>	<u>TX0008356757</u>	<u>2016</u>
<u>IPD Rx Insights: Future Budget Buster Nonalcoholic Steatohepatitis (NASH)</u>	<u>TX0008356837</u>	<u>2016</u>

<u>JAWBONE VS FITBIT: JAWBONE'S LAWSUITS AGAINST FITBIT APPEAR TO PRESENT MARGINAL RISK TO FITBIT.</u>	<u>TX0008224438</u>	<u>2015</u>
<u>INJ V. BSX: AN OVERVIEW OF UPCOMING TRIAL IN GUIDANT MERGER BREACH OF CONTRACT DISPUTE.</u>	<u>TX0008018440</u>	<u>2014</u>
<u>Juxtapid (AEGR): Dosing Patent Likely To Protect Juxtapid From Generic Competition Until 2027.</u>	<u>TX0007777006</u>	<u>2013</u>
<u>Jynarque (tolvaptan)</u>	<u>TX0008812817</u>	<u>2018</u>
<u>KCI v. SNN (NPWT Systems): Jury Trial Begins Tomorrow.</u>	<u>TX0007379603</u>	<u>2010</u>
<u>KEY CONSIDERATIONS FOR THE MEDICARE 2020 PROPOSED RULE TO LOWER DRUG PRICES AND REDUCE OUT-OF-POCKET COSTS.</u>	<u>TX0008794305</u>	<u>2018</u>
<u>KIDNEY DISEASE: SENSIPAR VS. PARSABIV.</u>	<u>TX0008808078</u>	<u>2018</u>
<u>Krintafel (tafenoquine)</u>	<u>TX0008789525</u>	<u>2018</u>
<u>LadaTech v. Illumina (ILMN): An Initial Look At The Patent Infringement Lawsuit.</u>	<u>TX0007482304</u>	<u>2011</u>
<u>Landscape of Advanced and Metastatic Non-Small Cell Lung Cancer (NSCLC)</u>	<u>TX0008394088</u>	<u>2016</u>
<u>Lantus and LY2963016 (SNY, LLY): An Early Look At The Patent Lawsuit.</u>	<u>TX0007947770</u>	<u>2014</u>
<u>Lantus and Other Products That Will Be Affected by FDA Transition from NDA to BLA in 2020 ? One Year Until Kickoff.</u>	<u>TX0008802443</u>	<u>2019</u>
<u>Laquinimod (TEVA): An Early Look At The Laquinimod Patent Situation.</u>	<u>TX0007387907</u>	<u>2010</u>
<u>LDL Management PCSK9 and Pipeline Update.</u>	<u>TX0008425473</u>	<u>2016</u>
<u>LDL Management: Zetia / Vytorin Update.</u>	<u>TX0008425470</u>	<u>2016</u>
<u>Lialda (Shire v. Zydus): An Initial Look At The Litigation Over A Proposed Generic Version Of Lialda.</u>	<u>TX0007472483</u>	<u>2011</u>
<u>Lialda (SHPG v. ACT): A Preview Of The Coming Trial.</u>	<u>TX0007720755</u>	<u>2013</u>

<u>LIALDA (SHPG v. AGN): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008224101</u>	<u>2016</u>
<u>LIALDA (SHPG v. ZYDUS): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008356764</u>	<u>2016</u>
<u>Libtayo (cemiplimab-rwlc)</u>	<u>TX0008812917</u>	<u>2018</u>
<u>Lidoderm (ENDP): Heading Into Trial. TWI Appears To Have Advantage.</u>	<u>TX0007947761</u>	<u>2014</u>
<u>Lidoderm (ENDP v. WPD): Endo Appears To Have Advantage Heading Into Markman Hearing.</u>	<u>TX0007416029</u>	<u>2011</u>
<u>Lidoderm (ENDP WPD): An Early Look At The Endo v. Watson Lawsuit.</u>	<u>TX0007392913</u>	<u>2011</u>
<u>Life and Cornell University v. Illumina (LIFE ILMN): An Early Look At Another Life v. Illumina Lawsuit.</u>	<u>TX0007379613</u>	<u>2010</u>
<u>Life (LIFE) v. Illumina (ILMN): An Overview Of The Patent Lawsuits Currently Pending Between Life And Illumina.</u>	<u>TX0007622308</u>	<u>2012</u>
<u>Life v. Illumina: An Early Look At The Recent Life v. Illumina Lawsuit.</u>	<u>TX0007379607</u>	<u>2010</u>
<u>Life v. Illumina (LIFE ILMN): Life Appears To Have The Overall Advantage, But Likely It Must Go To Trial To Prevail.</u>	<u>TX0007443257</u>	<u>2011</u>
<u>Lifecycle Management and New Competition: Treanda, Bendeka and Bendamustine RTD.</u>	<u>TX0008812674</u>	<u>2018</u>
<u>Lokelma (sodium zirconium cyclosilicate)</u>	<u>TX0008813381</u>	<u>2018</u>
<u>Lorbrena (lorlatinib)</u>	<u>TX0008793400</u>	<u>2018</u>
<u>Lovaza (Pronova, GSK v. TEVA, Apotex, PRX): Pronova Appears To Have Advantage On Excluding Competition Until At Least 2013.</u>	<u>TX0007388004</u>	<u>2010</u>
<u>Lovaza (Pronova v. Teva, Par): Although a Close Call, Lovaza 2013 and 2017 Patents Likely Invalid.</u>	<u>TX0007426007</u>	<u>2011</u>
<u>Lucemyra (lofexidine)</u>	<u>TX0008814129</u>	<u>2018</u>
<u>Lumigan (AGN, TEVA, Sandoz): Allergan Appears To Have Advantage In Patent Lawsuit Heading Into Trial.</u>	<u>TX0007387995</u>	<u>2011</u>

<u>Lumigan: Allergan Appears To Have Advantage In Patent Lawsuit.</u>	<u>TX0007388070</u>	<u>2010</u>
<u>Lumoxiti (moxetumomab pasudotox-fdtk)</u>	<u>TX0008812838</u>	<u>2018</u>
<u>Lutathera (lutetium Lu 177 dotatate)</u>	<u>TX0008813865</u>	<u>2018</u>
<u>Lyrica (PFE): Pfizer Composition-Of-Matter Patent Likely Will Prevent Generic Competition Until December 2018.</u>	<u>TX0007387982</u>	<u>2011</u>
<u>LYRICA (PREGABALIN) CAPSULES GENERIC LAUNCH FORECAST: Low-cost Generics and Extensive Conversion Expected in H2 2019.</u>	<u>TX0008812771</u>	<u>2018</u>
<u>MAKENA FINANCIAL FORECAST: AMAG'S LIFE CYCLE MANAGEMENT STRATEGY LIKELY WILL PRESERVE BRAND SHARE.</u>	<u>TX0008814179</u>	<u>2018</u>
<u>MAKENA FINANCIAL FORECAST UPDATE: FIRST GENERIC ENTRANTS LAUNCH.</u>	<u>TX0008814149</u>	<u>2018</u>
<u>Makena (hydroxyprogesterone caproate): Management and Cost.</u>	<u>TX0008784746</u>	<u>2018</u>
<u>Managed Care Organizations.</u>	<u>TX0008784795</u>	<u>2018</u>
<u>Management of therapy for Active Symptomatic Multiple Myeloma.</u>	<u>TX0008388263</u>	<u>2016</u>
<u>Managing Pulmonary Arterial Hypertension (PAH)</u>	<u>TX0008357299</u>	<u>2016</u>
<u>Masimo (MASI) v. Philips Update: Battle On Pulse Oximetry Patents Heads To First Trial In Mid-September.</u>	<u>TX0007952880</u>	<u>2014</u>
<u>Medicare Part B Step Therapy.</u>	<u>TX0008813233</u>	<u>2018</u>
<u>MEDICARE PART D 2019 FORMULARY GUIDANCE: Expedited Substitution of Certain Generics Creates Savings Opportunities for Part D Plans.</u>	<u>TX0008812695</u>	<u>2018</u>
<u>Medtronic (MDT) v. NuVasive (NUVA): First Phase Overview, Medtronic Appears To Have Slight Advantage.</u>	<u>TX0007379608</u>	<u>2010</u>

<u>Medtronic v. NuVasive (MDT NUVA): Hearing On Post-Trial Motions And Permanent Injunction Set For January 26.</u>	<u>TX0007544177</u>	<u>2012</u>
<u>Medtronic v. NuVasive (MDT NUVA): Trial Set To Begin August 30; Mixed Decision Appears Likely.</u>	<u>TX0007443267</u>	<u>2011</u>
<u>Mektovi (binimetinib)</u>	<u>TX0008789577</u>	<u>2018</u>
<u>Mentor v. Synopsys (MENT, SNPS): Mentor v. Synopsys: Mentor Has Narrow Overall Advantage Against Synopsys.</u>	<u>TX0007948116</u>	<u>2014</u>
<u>Metastatic Breast Cancer: New treatments for metastatic breast cancer.</u>	<u>TX0008781955</u>	<u>2017</u>
<u>Metastatic Breast Cancer: New treatments for metastatic breast cancer.</u>	<u>TX0008412321</u>	<u>2017</u>
<u>Migraine: CGRP Inhibitors ? New Migraine Mechanism of Action, Several in the Pipeline for Potential 2018 Approval.</u>	<u>TX0008782552</u>	<u>2017</u>
<u>MOBILEYE PATENTS MAY NOT DETER COMPETITORS.</u>	<u>TX0007987557</u>	<u>2014</u>
<u>Motegrity (pricalopride)</u>	<u>TX0008801758</u>	<u>2018</u>
<u>Movement Disorders: Drug Management Strategy.</u>	<u>TX0008412324</u>	<u>2017</u>
<u>MS Class Management.</u>	<u>TX0008226839</u>	<u>2015</u>
<u>Mucinex: An In-Depth Look at the Upcoming Mucinex Trial.</u>	<u>TX0007388012</u>	<u>2010</u>
<u>Mucinex: Appeals Court Appears Inclined To Vacate Perrigo's Summary Judgment Victory and Return Case to District Court.</u>	<u>TX0007388044</u>	<u>2010</u>
<u>Mulpleta (lusutrombopag)</u>	<u>TX0008789521</u>	<u>2018</u>
<u>Multaq (SNY): An Early Look At The Patent Litigation.</u>	<u>TX0007947993</u>	<u>2014</u>
<u>Myelodysplastic Syndrome (MDS): Drug Management Strategy.</u>	<u>TX0008412328</u>	<u>2017</u>
<u>Mylan's HIV 505b2s Provide Viable Alternatives to Established Brands at Lower Price Points.</u>	<u>TX0008812963</u>	<u>2018</u>

<u>Myriad (MYGN): Supreme Court To Consider Validity of Myriad Patents Covering Isolated DNA.</u>	<u>TX0007720751</u>	<u>2013</u>
<u>NAMENDA XR (AGN): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008356854</u>	<u>2016</u>
<u>NAMENDA XR (AGN): AN UPDATE ON THE LITIGATION REGARDING PROPOSED GENERIC NAMENDA XR.</u>	<u>TX0008783776</u>	<u>2017</u>
<u>Namenda XR Generic Launch Forecast.</u>	<u>TX0008814191</u>	<u>2017</u>
<u>Narcolepsy: Increased Competition May Reduce Xyrem Spend for Payers.</u>	<u>TX0008784778</u>	<u>2018</u>
<u>NASONEX (MRK): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008357286</u>	<u>2016</u>
<u>NASONEX (MRK): AN ANALYSIS REGARDING WHEN NASONEX MIGHT FACE GENERIC COMPETITION.</u>	<u>TX0008226844</u>	<u>2015</u>
<u>Nasonex (MRK, Apotex): An Early Look At The Merck v. Apotex Lawsuit.</u>	<u>TX0007387937</u>	<u>2011</u>
<u>Neulasta and Biosimilars.</u>	<u>TX0008807294</u>	<u>2019</u>
<u>NEULASTA; NEUPOGEN; EPOGEN/PROCRIT; REMICADE: UPCOMING COURT PROCEEDINGS MAY PERMIT BIOSIMILARS TO LAUNCH UPON FDA APPROVAL WITHOUT WAITING 180 DAYS.</u>	<u>TX0008224453</u>	<u>2015</u>
<u>NEUPOGEN (FILGRASTIM): COURT TO DECIDE WHETHER BIOSIMILAR PATENT DANCE IS OPTIONAL OR MANDATORY AND WHETHER 180-DAY NOTICE CAN BE GIVEN BEFORE APPROVAL.</u>	<u>TX0008224182</u>	<u>2015</u>
<u>Neupogen/Neuroval: An Early Look At The Neuroval Litigation.</u>	<u>TX0007387919</u>	<u>2010</u>
<u>Neurontin (PFE v. TEVA): Pfizer May Have Difficulty In Gabapentin Patent Infringement Trial.</u>	<u>TX0007423776</u>	<u>2011</u>
<u>NEVRO & BOSTON SCIENTIFIC: AN EARLY LOOK AT THE SPINAL CORD STIMULATION PATENT DISPUTES.</u>	<u>TX0008425465</u>	<u>2017</u>

<u>NEVRO (NVRO): NEVRO PATENT FACES SIGNIFICANT THREAT FROM BSX IPR PETITIONS.</u>	<u>TX0008169134</u>	<u>2015</u>
<u>New Bendamustine Competition: Eagle's Bendamustine RTD Impact on Teva's Bendeka and Treanda Sales.</u>	<u>TX0008814015</u>	<u>2018</u>
<u>New CDC Shingles Vaccine Recommendations: Shingrix.</u>	<u>TX0008789565</u>	<u>2018</u>
<u>New HCPCS Drug Codes Effective July 2018.</u>	<u>TX0008814030</u>	<u>2018</u>
<u>New HCPCS Drug Codes Effective October 2018.</u>	<u>TX0008812629</u>	<u>2018</u>
<u>NEW THERAPIES IN OVARIAN CANCER: Poly (ADP-ribose) polymerase (PARP) inhibitors.</u>	<u>TX0008387719</u>	<u>2016</u>
<u>Newer Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections (ABSSTI)</u>	<u>TX0008793373</u>	<u>2018</u>
<u>Nexium/ PPIs: Product Lifecycle Management.</u>	<u>TX0008226781</u>	<u>2015</u>
<u>Nokia v. Apple: ITC Patent Lawsuits Threaten Each Company's Key Products.</u>	<u>TX0007371746</u>	<u>2010</u>
<u>NOKIA v. APPLE: PATENT HOSTILITIES FLARE ONCE AGAIN.</u>	<u>TX0008414323</u>	<u>2017</u>
<u>Non-Oral Contraception Management: NuvaRing Generic Update.</u>	<u>TX0008387720</u>	<u>2016</u>
<u>Non-Small Cell Lung Cancer Update: PD-1 and PD-L1 Inhibitors.</u>	<u>TX0008394085</u>	<u>2016</u>
<u>NUCYNTA & NUCYNTA ER (DEPO): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008356766</u>	<u>2016</u>
<u>NUCYNTA & NUCYNTA ER (DEPO): AN OVERVIEW OF THE PATENT LITIGATION.</u>	<u>TX0008169145</u>	<u>2015</u>
<u>Nuedexta (AVNR): An Initial Look.</u>	<u>TX0007595625</u>	<u>2012</u>
<u>NUVARING GENERIC FORECAST.</u>	<u>TX0008814452</u>	<u>2019</u>
<u>NuVasive v. Globus: An Early Look At The NuVasive v. Globus Lawsuit.</u>	<u>TX0007427934</u>	<u>2011</u>
<u>Nuvigil (TEVA v. MYL): An Initial Look At The Litigation Over Proposed Generic Versions Of Nuvigil.</u>	<u>TX0007464630</u>	<u>2011</u>

<u>Nuzyra (omadacycline)</u>	<u>TX0008812835</u>	<u>2018</u>
<u>NVIDIA v. SAMSUNG AND QUALCOMM: AN EARLY LOOK AT THE ITC LAWSUIT.</u>	<u>TX0008018453</u>	<u>2014</u>
<u>OBALON: INITIAL LOOK AT INTRAGASTRIC BALLOON PATENTS.</u>	<u>TX0008783782</u>	<u>2017</u>
<u>Ofirmev (Cadence): Cadence Appears To Have Advantage On Preventing Generic Competition Until 2018.</u>	<u>TX0007622305</u>	<u>2012</u>
<u>Olumiant (baricitinib)</u>	<u>TX0008812815</u>	<u>2018</u>
<u>Omegaven (fish oil triglycerides) injectable emulsion.</u>	<u>TX0008812622</u>	<u>2018</u>
<u>ONFI (CLOBAZAM) GENERIC LAUNCH FORECAST: Tablets and Suspension Likely to Experience Generic Competition in 2018.</u>	<u>TX0008812844</u>	<u>2018</u>
<u>Onpattro (patisiran)</u>	<u>TX0008812597</u>	<u>2018</u>
<u>OPANA ER (ENDP): HEADING INTO TRIAL. ENDO APPEARS TO HAVE THE ADVANTAGE.</u>	<u>TX0008357284</u>	<u>2016</u>
<u>Opioid Addiction: Buprenorphine Class Management.</u>	<u>TX0008783775</u>	<u>2017</u>
<u>Oracle (ORCL) v. Google (GOOG): Appeals Court Likely To Issue Decision That Favors Oracle.</u>	<u>TX0007947710</u>	<u>2014</u>
<u>Oracle v. Google: Oracle Holds Early Advantage Against Google.</u>	<u>TX0007371722</u>	<u>2010</u>
<u>Oral Antiplatelet Agents Acute Coronary Syndrome (ACS) or Coronary Stent Generic Effient Opportunity.</u>	<u>TX0008226845</u>	<u>2015</u>
<u>Orilissa (elagolix)</u>	<u>TX0008814132</u>	<u>2018</u>
<u>Osteoarthritis of the Knee ? Steroid Injection Management.</u>	<u>TX0008807668</u>	<u>2018</u>
<u>Osteoporosis: Drug Management Strategy.</u>	<u>TX0008414313</u>	<u>2017</u>
<u>Osteoporosis: Forecast Model Inputs.</u>	<u>TX0008809555</u>	<u>2018</u>
<u>OTICON V. GN RESOUND (WDH:DC, GN:DC): VALIDITY OF OTICON PATENTS APPEARS VULNERABLE.</u>	<u>TX0008224440</u>	<u>2015</u>

<u>Otrexup (ATRS): An Overview Of Antares' Attempt To Block Medac's Launch Of Rasuvo.</u>	<u>TX0007947995</u>	<u>2014</u>
<u>Over \$9 Billion in Generic Launches to Impact Pharmaceutical Management and Drug Budgets over the Next 90 Days.</u>	<u>TX0008425475</u>	<u>2017</u>
<u>OVERVIEW OF DEPOMED'S PATENT INFRINGEMENT LAWSUITS AGAINST PURDUE AND ENDO.</u>	<u>TX0008169136</u>	<u>2015</u>
<u>OVERVIEW OF J2 GLOBAL'S PATENT PORTFOLIO.</u>	<u>TX0008357282</u>	<u>2016</u>
<u>Overview of Nokia's Patent Monetization Posture.</u>	<u>TX0007948135</u>	<u>2014</u>
<u>OVERVIEW OF POTENTIAL COMPETITION TO BENDAMUSTINE PRODUCTS.</u>	<u>TX0008357277</u>	<u>2016</u>
<u>Overview Of Potential Generic Competition To Controlled-Release Mesalamine Products.</u>	<u>TX0007622311</u>	<u>2012</u>
<u>Oxervate (cenegermin-bkbi)</u>	<u>TX0008806618</u>	<u>2018</u>
<u>OXTELLAR XR AND TROKENDI XR (SUPN): A LOOK AT TWO SETS OF SUPERNUS PATENTS.</u>	<u>TX0008114946</u>	<u>2015</u>
<u>OxyContin (Purdue): A Preview Of The Coming Trial.</u>	<u>TX0007948014</u>	<u>2014</u>
<u>OxyContin (Purdue): A Preview Of The Coming Trial.</u>	<u>TX0007824325</u>	<u>2013</u>
<u>Pain: Drug Management Strategy.</u>	<u>TX0008414266</u>	<u>2017</u>
<u>Palomar v. Syneron: Palomar Appears To Have Early Advantage In Lawsuit.</u>	<u>TX0007379922</u>	<u>2010</u>
<u>Palynziq (pegvaliase-pqpz)</u>	<u>TX0008807772</u>	<u>2018</u>
<u>PARSABIV FINANCIAL FORECAST: Gradual Uptake Will Result In Moderate Growth Through 2023.</u>	<u>TX0008789568</u>	<u>2018</u>
<u>Patanol (ACL): Although a Close Call, Alcon Appears to Have the Advantage in Excluding Generic Competition Until 2015.</u>	<u>TX0007387944</u>	<u>2010</u>
<u>PCSK9 ANTIBODIES: AMGEN PATENT THREATENS COMPETITORS; EPO OPPOSITION AND UK COURT CHALLENGES PENDING.</u>	<u>TX0008356805</u>	<u>2016</u>

<u>PCSK9 ANTIBODIES (AMGN V. REGN & SNY): JURY TRIAL AND INJUNCTION HEARING SCHEDULED FOR MARCH 2016.</u>	<u>TX0008224441</u>	<u>2015</u>
<u>PCSK9 INHIBITOR FINANCIAL FORECAST.</u>	<u>TX0008808658</u>	<u>2019</u>
<u>PCSK9: LDL Class Management.</u>	<u>TX0008226841</u>	<u>2015</u>
<u>PCSK9: LDL Class Management Praluent Approval Update.</u>	<u>TX0008226842</u>	<u>2015</u>
<u>PCSK9: LDL Class Management Update.</u>	<u>TX0008226871</u>	<u>2015</u>
<u>PD-L1 ANTIBODIES: AN EARLY LOOK AT BMS'S NEW LAWSUITS.</u>	<u>TX0008783768</u>	<u>2017</u>
<u>PD-L1 ANTIBODIES: AN OVERVIEW OF THE EUROPEAN PATENT DISPUTE.</u>	<u>TX0008814044</u>	<u>2018</u>
<u>PDE-5 / ED Class Management : \$1 opportunity?</u>	<u>TX0008226786</u>	<u>2015</u>
<u>PENNSAID 2%(HZNP): AN EARLY LOOK AT THE PATENT LITIGATION.</u>	<u>TX0008224436</u>	<u>2015</u>
<u>Philips v. Zoll Medical: An Early Look.</u>	<u>TX0007379609</u>	<u>2010</u>
<u>Pirfenidone: An Early Look at the Pirfenidone Patent Situation.</u>	<u>TX0007388061</u>	<u>2010</u>
<u>PLACENTAL TISSUE GRAFTS (MDXG): VALIDITY OF MDXG PATENTS APPEARS VULNERABLE.</u>	<u>TX0008114936</u>	<u>2015</u>
<u>PNH: Paroxysmal Nocturnal Hemoglobinuria.</u>	<u>TX0008793398</u>	<u>2018</u>
<u>Pomalidomide: An Early Look At The Pomalidomide Patent Situation.</u>	<u>TX0007387917</u>	<u>2010</u>
<u>Post-Surgical Pain Management: Local Analgesics.</u>	<u>TX0008808646</u>	<u>2019</u>
<u>Poteligeo (mogamulizumab-kpkc) injection.</u>	<u>TX0008812585</u>	<u>2018</u>
<u>Pradaxa (Boehringer Ingelheim): An Overview Of The Patent Portfolio For Pradaxa.</u>	<u>TX0007947769</u>	<u>2014</u>
<u>Precedex (HSP): Hospira Has Advantage On 2013 Patent, But Too Early To Assess 2019 Patent.</u>	<u>TX0007387980</u>	<u>2011</u>
<u>PRELIMINARY LANDSCAPE VIEW OF CRISPR.</u>	<u>TX0008356819</u>	<u>2016</u>

<u>Previmis : Approved to treat cytomegalovirus infection.</u>	<u>TX0008784094</u>	<u>2017</u>
<u>Prezista (JNJ): Prezista May Face Generic Competition in 2019.</u>	<u>TX0007824322</u>	<u>2013</u>
<u>Proair HFA (TEVA v. PRGO): Perrigo May Launch Generic As Early As 2017.</u>	<u>TX0007947724</u>	<u>2014</u>
<u>PRODUCTS LIKELY TO BE AFFECTED BY INTER PARTES REVIEW (?IPR?) PROCEEDINGS.</u>	<u>TX0008224140</u>	<u>2015</u>
<u>Prometheus v. Mayo: Supreme Court To Consider Patentability Of Certain Medical Technology Methods.</u>	<u>TX0007482309</u>	<u>2011</u>
<u>PROSTATE CANCER FORECAST UPDATE: Recent Approvals and Upcoming Launch of Generic Zytiga Likely Will Ensure Continued Market Growth.</u>	<u>TX0008816892</u>	<u>2018</u>
<u>Pulmicort Respules (AZN v. WPI, Apotex, NVS): An Overview Of The Litigation.</u>	<u>TX0007595629</u>	<u>2012</u>
<u>Pulmicort Respules (AZN v. WPI, Apotex, NVS): Heading Into Trial, AstraZeneca Appears To Have Advantage.</u>	<u>TX0007622297</u>	<u>2012</u>
<u>Obrexza (glycopyrronium)</u>	<u>TX0008812765</u>	<u>2018</u>
<u>Onexa (VVUS): An Overview Of The Onexa Patent Situation.</u>	<u>TX0007544100</u>	<u>2012</u>
<u>QUALCOMM: OVERVIEW OF ANTITRUST & PATENT INFRINGEMENT LAWSUITS.</u>	<u>TX0008808085</u>	<u>2018</u>
<u>Radicava (edaravone): For amyotrophic lateral sclerosis (ALS)</u>	<u>TX0008457624</u>	<u>2017</u>
<u>Radicava (edaravone):For amyotrophic lateral sclerosis (ALS)</u>	<u>TX0008415907</u>	<u>2017</u>
<u>Rambus: Rambus At Risk Of Adverse Outcome In Spoliation Appeals; Appeals Decisions May Jeopardize Other Rambus Lawsuits.</u>	<u>TX0007371742</u>	<u>2010</u>
<u>Rambus v. Micron & Hynix : Appeals Court Likely Will Rule Against Rambus On Spoliation But Likely Will Vacate And Remand Unenforceability Sanction.</u>	<u>TX0007371723</u>	<u>2010</u>
<u>RAPTOR (RPTP): A LOOK AT THE PROCYSBI PATENT SITUATION.</u>	<u>TX0008018458</u>	<u>2014</u>

<u>RAVICTI (HZNP): A REVIEW OF HORIZON'S PATENT PROTECTION FOR RAVICTI AFTER 2020.</u>	<u>TX0008809486</u>	<u>2018</u>
<u>REMODULIN (UTHR): A LOOK AT SECOND WAVE LAWSUITS.</u>	<u>TX0008018450</u>	<u>2014</u>
<u>Remodulin (UTHR v. NVS): Remodulin Faces Threat Of Generic Competition In Q4 2014.</u>	<u>TX0007544085</u>	<u>2012</u>
<u>Renal cell carcinoma: Therapy and management of medications.</u>	<u>TX0008785848</u>	<u>2017</u>
<u>REPATHA PRICE REDUCTION ? Will It Change Utilization?</u>	<u>TX0008817286</u>	<u>2018</u>
<u>ResMed v. Apex and BMC: An Early Look At The Patent Disputes.</u>	<u>TX0007947722</u>	<u>2014</u>
<u>Restasis (AGN): A Close Look At Allergan's Patent Protection For Restasis.</u>	<u>TX0007947765</u>	<u>2014</u>
<u>RESTASIS (AGN): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008783779</u>	<u>2017</u>
<u>RESTASIS GENERIC LAUNCH FORECAST: Uncertain Launch Timing and Complex Formulation Likely Will Delay Price Erosion and Slow Uptake.</u>	<u>TX0008789575</u>	<u>2018</u>
<u>Retacrit (epoetin-alpha-epbx)</u>	<u>TX0008812642</u>	<u>2018</u>
<u>Revcovi (elapegademase-tyvir): for adults and pediatric patients with adenosine deaminase severe combined immune deficiency.</u>	<u>TX0008812786</u>	<u>2018</u>
<u>Revlimid (CELG): An Analysis Of The Polymorph Patent Family.</u>	<u>TX0007544161</u>	<u>2012</u>
<u>REVLIMID (CELG): NATCO DISCLOSES ITS POLYMORPH; GENERIC COMPETITION EXPECTED IN 2019 OR 2023.</u>	<u>TX0008114783</u>	<u>2015</u>
<u>Revlimid (Lenalidomide) Global Insights Report: European Oppositions Threaten Revlimid Patents; Provide Insight Into U.S. Challenges.</u>	<u>TX0007948150</u>	<u>2014</u>
<u>RITUXAN: BIOSIMILAR COMPETITION EXPECTED BY JULY 2018.</u>	<u>TX0008224461</u>	<u>2016</u>
<u>ROVI v. COMCAST: AN EARLY LOOK AT ROVI'S ITC LAWSUIT.</u>	<u>TX0008356797</u>	<u>2016</u>
<u>ROVI v. NETFLIX: AN EARLY LOOK AT ROVI'S APPEAL.</u>	<u>TX0008357303</u>	<u>2016</u>

<u>Rydapt (midostaurin): Uses and utilization Management.</u>	<u>TX0008414294</u>	<u>2017</u>
<u>SAMSUNG v. NVIDIA: SAMSUNG LAWSUITS PRESENT CREDIBLE COUNTERTHREAT TO NVIDIA.</u>	<u>TX0008169126</u>	<u>2015</u>
<u>Sanctura XR (AGN v WPI, NVS, Paddock): An Early Look.</u>	<u>TX0007388047</u>	<u>2010</u>
<u>Savella (ACT): An Early Look At The Patent Litigation.</u>	<u>TX0007948019</u>	<u>2014</u>
<u>SENSIPAR GENERIC LAUNCH FORECAST: Competitive Market with Low-Cost Generics Likely to Facilitate Rapid and Extensive Generic Uptake.</u>	<u>TX0008789564</u>	<u>2018</u>
<u>Sequenom/Lo (SQNM) And Verinata/Quake: The Patent Landscape For Prenatal Down Syndrome Diagnosis.</u>	<u>TX0007443270</u>	<u>2011</u>
<u>Sequenom, Verinata, Ariosa, & Natera: An Overview Of The Patent Landscape And Upcoming Markman Hearings.</u>	<u>TX0007824323</u>	<u>2013</u>
<u>Seysara (sarecycline)</u>	<u>TX0008817289</u>	<u>2018</u>
<u>SHIRE APPEARS TO HAVE ADVANTAGE IN PATENT LAWSUIT INVOLVING CSL BEHRING'S HAEGARDA.</u>	<u>TX0008785269</u>	<u>2017</u>
<u>SHORT-ACTING BETA AGONIST (ALBUTEROL) GENERIC FORECAST.</u>	<u>TX0008808649</u>	<u>2019</u>
<u>Significant Uptake Likely for Hereceptin Biosimilars.</u>	<u>TX0008814462</u>	<u>2019</u>
<u>Silenor: Patent Likely To Prevent Generic Competition Until 2020.</u>	<u>TX0007388031</u>	<u>2010</u>
<u>SIRONA DENTAL (SIRO): AN EARLY LOOK AT THE PETITIONS FOR IPR PROCEEDINGS.</u>	<u>TX0008169332</u>	<u>2015</u>
<u>Sleep Disorders: Drug Management Strategy.</u>	<u>TX0008783774</u>	<u>2017</u>
<u>SOME THOUGHTS ON THE INTERPLAY BETWEEN DISTRICT COURT LITIGATION AND INTER PARTES REVIEW (?IPR?) PROCEEDINGS.</u>	<u>TX0008357280</u>	<u>2016</u>
<u>Spinraza (nusinersen) /Biogen: A medication for Spinal Muscular Atrophy.</u>	<u>TX0008425478</u>	<u>2017</u>

<u>Spravato (esketamine) nasal spray.</u>	<u>TX0008814480</u>	<u>2019</u>
<u>St. Jude Medical (STJ) v. W.L. Gore: An Initial Look At The Helex Septal Occluder Lawsuit.</u>	<u>TX0007606275</u>	<u>2012</u>
<u>St. Jude Medical (STJ) v. W.L. Gore: An Initial Look At The Helex Septal Occluder Lawsuit.</u>	<u>TX0007595638</u>	<u>2012</u>
<u>St. Jude V. Volcano (STJ VOLC): A Survey Of The Parties' Lawsuits.</u>	<u>TX0007379611</u>	<u>2010</u>
<u>Strattera: Appeals Court Appears Inclined To Rule For Lilly And Prevent Generic Competition Until May 2017.</u>	<u>TX0007387952</u>	<u>2010</u>
<u>Strattera: Generics Appear To Have Advantage In Proving Lilly's Strattera Patent Invalid.</u>	<u>TX0007388042</u>	<u>2010</u>
<u>Suboxone Film (Reckitt Benckiser): An Early Look At The Patent Litigation.</u>	<u>TX0007824326</u>	<u>2013</u>
<u>SUBOXONE (INDV): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008224102</u>	<u>2015</u>
<u>SUBOXONE (INDV): A PREVIEW OF THE COMING TRIALS.</u>	<u>TX0008357068</u>	<u>2016</u>
<u>Subsys (INSY): Insys's Subsys Likely Protected From Generic Competition Until 2027.</u>	<u>TX0007948000</u>	<u>2014</u>
<u>Sunovion's Latuda Likely Protected From Generic Competition Until At Least 2018.</u>	<u>TX0007948029</u>	<u>2014</u>
<u>SUPREME COURT LIKELY TO REQUIRE DEFERENCE TO TRIAL COURT DECISIONS INTERPRETING PATENTS.</u>	<u>TX0008018448</u>	<u>2014</u>
<u>SUPREME COURT TO REVIEW CONSTITUTIONALITY OF INTER PARTES REVIEW ("IPR") PROCEEDINGS.</u>	<u>TX0008785262</u>	<u>2017</u>
<u>Survey Of Apple's Patent Infringement Lawsuits.</u>	<u>TX0007371741</u>	<u>2010</u>
<u>Symdeko (tezacaftor/ivacaftor and ivacaftor): Cystic Fibrosis.</u>	<u>TX0008807671</u>	<u>2018</u>
<u>TAKHZYRO FINANCIAL FORECAST: Shire likely to corner the Hereditary Angioedema market with both prophylactic and acute treatments.</u>	<u>TX0008816979</u>	<u>2018</u>
<u>Takhzyro (lanadelumab-flyo)</u>	<u>TX0008812819</u>	<u>2018</u>
<u>Talzenna (talazoparib)</u>	<u>TX0008812958</u>	<u>2018</u>

<u>Tamiflu: Generic Outlook.</u>	<u>TX0008394086</u>	<u>2016</u>
<u>TARCEVA (ERLOTINIB) GENERIC LAUNCH FORECAST: Generic Entry and Extensive Conversion Expected in 2019.</u>	<u>TX0008812685</u>	<u>2018</u>
<u>Tavalisse (fostamatinib disodium hexahydrate)</u>	<u>TX0008808082</u>	<u>2018</u>
<u>Taxotere (SNY, HSP, APOTEX): Although A Close Call, District Court Likely Will Issue Decision In Favor of Sanofi.</u>	<u>TX0007388064</u>	<u>2010</u>
<u>TECFIDERA (DIMETHYL FUMARATE): NOVEMBER 30 HEARINGS SCHEDULED TO DECIDE INTERFERENCE AND IPR PROCEEDINGS.</u>	<u>TX0008357028</u>	<u>2016</u>
<u>TECFIDERA (DIMETHYL FUMARATE): NOVEMBER 30 HEARINGS SCHEDULED TO DECIDE INTERFERENCE AND IPR PROCEEDINGS.</u>	<u>TX0008425462</u>	<u>2016</u>
<u>TECFIDERA (DIMETHYL FUMARATE) REPORT (BIIB, FWP): EPO TO DECIDE VALIDITY OF 2028 DOSING PATENT MARCH 8-11; GERMAN COURT TO HEAR FORWARD'S LAWSUIT MARCH 24.</u>	<u>TX0008356765</u>	<u>2016</u>
<u>Tegsedi (inotersen)</u>	<u>TX0008812655</u>	<u>2018</u>
<u>Temodar: Although A Close Call, Upcoming Appeals Court Decision Most Likely Will Permit Teva To Launch Generic Temodar.</u>	<u>TX0007387927</u>	<u>2010</u>
<u>Temodar: Teva Has Advantage Entering August 4 Appeal Hearing.</u>	<u>TX0007387933</u>	<u>2010</u>
<u>Testim (AUXL, WPD): An Early Look At The Coming Auxilium v. Watson Lawsuit.</u>	<u>TX0007544030</u>	<u>2012</u>
<u>Testosterone Management: Axiron Generic Update.</u>	<u>TX0008414268</u>	<u>2016</u>
<u>THROMBOCYTOPENIA IN CHRONIC LIVER DISEASE FINANCIAL FORECAST: WITH LIMITED CLINICAL DIFFERENTIATION, DOPTELET AND MULPLETA WILL COMPETE ON PRICE.</u>	<u>TX0008812682</u>	<u>2018</u>
<u>Tibsovo (ivosidenib)</u>	<u>TX0008809504</u>	<u>2018</u>
<u>TIVO v. SAMSUNG: AN EARLY LOOK AT THE LAWSUIT.</u>	<u>TX0008356915</u>	<u>2016</u>

<u>Travatan and Travatan Z (NVS, PRX, TEVA): An Initial Look.</u>	<u>TX0007427932</u>	<u>2011</u>
<u>Travatan and Travatan Z (NVS V PAR, TEVA): Trial Begins This Week.</u>	<u>TX0007472485</u>	<u>2011</u>
<u>Travelers? Diarrhea and Irritable Bowel Syndrome.</u>	<u>TX0008807273</u>	<u>2019</u>
<u>TREAND (TEVA): HEADING INTO MARKMAN HEARING, TEVA APPEARS TO HAVE ADVANTAGE.</u>	<u>TX0008114906</u>	<u>2015</u>
<u>TREANDA (TEVA): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008224443</u>	<u>2015</u>
<u>TREANDA (TEVA): AN EARLY LOOK AT THE PATENT LITIGATION.</u>	<u>TX0007987550</u>	<u>2014</u>
<u>Treanda (Teva) Lifecycle Management: Generic Outlook.</u>	<u>TX0008394076</u>	<u>2016</u>
<u>Treximet: An In-Depth Look at the Treximet Patent Situation.</u>	<u>TX0007388021</u>	<u>2010</u>
<u>Trogarzo (Ibalizumab/TMB-355): Multi-Drug Resistant HIV.</u>	<u>TX0008807806</u>	<u>2018</u>
<u>Truvada & Atripla (GILD TEVA): Gilead Has Advantage Defending Drugs From Generic Competition Until 2021.</u>	<u>TX0007387920</u>	<u>2010</u>
<u>Truvada & Atripla (GILD v. TEVA): Heading Into Trial, Gilead Appears To Have Advantage.</u>	<u>TX0007824328</u>	<u>2013</u>
<u>Tyrosine Kinase Inhibitors: Gleevec generic planning.</u>	<u>TX0008226782</u>	<u>2015</u>
<u>Tyrosine Kinase Inhibitors (TKIs): Gleevec generic planning.</u>	<u>TX0008388261</u>	<u>2016</u>
<u>U.S. PATENT LANDSCAPE AROUND FIBROGEN AND AKEBIA.</u>	<u>TX0008224442</u>	<u>2015</u>
<u>Ulcerative Colitis / Oral Mesalamine Management.</u>	<u>TX0008394089</u>	<u>2016</u>
<u>Ultomiris (ravulizumab-cwvz)</u>	<u>TX0008801785</u>	<u>2018</u>
<u>Understanding the 505(b)(2) Pathway.</u>	<u>TX0008357087</u>	<u>2016</u>
<u>Updated Atrial Fibrillation Treatment Guidelines January 2019.</u>	<u>TX0008814467</u>	<u>2019</u>
<u>UPDATED IPR STATISTICS IN THE PHARMACEUTICAL SECTOR.</u>	<u>TX0008226783</u>	<u>2015</u>

<u>USE OF THE 505(B)(2) NDA FOR EARLY MARKET ENTRY.</u>	<u>TX0008226784</u>	<u>2015</u>
<u>USE OF THE 505(B)(2) NDA FOR EARLY MARKET ENTRY : UNDERSTANDING OPPORTUNITIES AND PAYER CONSIDERATIONS.</u>	<u>TX0008784091</u>	<u>2017</u>
<u>Uterine fibroids: Current and pipeline therapies.</u>	<u>TX0008783771</u>	<u>2017</u>
<u>Vaginal Estrogen Management: Vagifem Generic Update.</u>	<u>TX0008388265</u>	<u>2016</u>
<u>VASCEPA'S REDUCE-IT Trial ? Will It Create a Paradigm Shift?</u>	<u>TX0008812677</u>	<u>2018</u>
<u>VEGF Therapies for Ophthalmic Conditions.</u>	<u>TX0008412345</u>	<u>2017</u>
<u>VEGF Trap-Eye (REGN v. Roche): An Early Look At The VEGF Trap-Eye Litigation.</u>	<u>TX0007387908</u>	<u>2011</u>
<u>Velcade (Millennium v. Sandoz): Velcade Unlikely To Face Generic Competition Before 2022.</u>	<u>TX0007595631</u>	<u>2012</u>
<u>Velcade (Millennium): Velcade Unlikely To Face Generic Competition Before 2022.</u>	<u>TX0007846276</u>	<u>2013</u>
<u>Viagra (PFE): Pfizer Has Advantage Defending Viagra From Generic Competition Until 2019.</u>	<u>TX0007387986</u>	<u>2010</u>
<u>Viagra (PFE v. TEVA): Heading Into Trial, Pfizer Appears To Have Advantage.</u>	<u>TX0007416034</u>	<u>2011</u>
<u>Vilbryd/Vilazodone Report (CLDA): An Initial Look at the Vilazodone Patent Situation.</u>	<u>TX0007387972</u>	<u>2011</u>
<u>Vimovo (AZN, POZN, RDY): An Initial Look At The Vimovo Patent Situation.</u>	<u>TX0007387912</u>	<u>2011</u>
<u>VIMOVO (POZN, HZNP): DR. REDDY'S ATTEMPTS TO DESIGN AROUND EXPANDING VIMOVO PATENT PORTFOLIO.</u>	<u>TX0008224136</u>	<u>2015</u>
<u>VIMPAT (UCB): AN EARLY LOOK AT THE PATENT LITIGATION.</u>	<u>TX0008018459</u>	<u>2014</u>
<u>VIMPAT (UCB): HEADING INTO TRIAL, UCB APPEARS TO HAVE THE ADVANTAGE.</u>	<u>TX0008224104</u>	<u>2015</u>
<u>VirnetX v. Apple (VHC AAPL): Federal Circuit Likely Will Affirm Infringement And Validity</u>	<u>TX0007947704</u>	<u>2014</u>

<u>Verdicts That Favor VirnetX But Remand Lawsuit For New Trial On Damages.</u>		
<u>Viscosupplements: Drug Management Strategy.</u>	<u>TX0008782561</u>	<u>2017</u>
<u>Vitrakvi (larotrectinib)</u>	<u>TX0008802449</u>	<u>2018</u>
<u>Vizimpro (dacomitinib)</u>	<u>TX0008812651</u>	<u>2018</u>
<u>Volterra v. Infineon: Jury Trial on Patent Validity Begins Today (Monday, May 9)</u>	<u>TX0007424317</u>	<u>2011</u>
<u>Vringo v. Google: Vringo Has Advantage Using Appeal to Increase Damage Award.</u>	<u>TX0007948140</u>	<u>2014</u>
<u>Vytorin and Zetia (MRK): Judge Appears Concerned About Validity And Enforceability of Merck's Patent.</u>	<u>TX0007544098</u>	<u>2012</u>
<u>W.L. GORE v. C.R. BARD (BCR): A LOOK AT THE REQUESTS FOR SUMMARY JUDGMENT.</u>	<u>TX0008224143</u>	<u>2015</u>
<u>W.L. Gore v. Medtronic (MDT): Lawsuit Does Not Threaten Medtronic's Talent Stent Graft Products.</u>	<u>TX0007443251</u>	<u>2011</u>
<u>Xarelto (JNJ, BAY): Janssen's Xarelto Likely Protected From Generic Competition Until 2024.</u>	<u>TX0007947763</u>	<u>2014</u>
<u>Xeljanz (PFE): Pfizer's Xeljanz Likely Protected From Generic Competition Until 2025.</u>	<u>TX0007947726</u>	<u>2014</u>
<u>Xerava (eravacycline)</u>	<u>TX0008817291</u>	<u>2018</u>
<u>Xgeva: Clinical Efficacy and Utilization Management.</u>	<u>TX0008789576</u>	<u>2018</u>
<u>Xifaxan (SLXP): An Overview Of Salix's Patent Portfolio For Xifaxan 550 mg And 200 mg.</u>	<u>TX0007777003</u>	<u>2013</u>
<u>Xifaxan (SLXP): An Updated Overview Of Salix's Patent Protection For Xifaxan 550 mg And 200 mg.</u>	<u>TX0007953030</u>	<u>2014</u>
<u>XIFAXAN (VRX): AN UPDATED OVERVIEW OF THE PATENT PORTFOLIO FOR XIFAXAN 550 MG AND 200 MG.</u>	<u>TX0008169147</u>	<u>2015</u>
<u>Xofluza (baloxavir marboxil)</u>	<u>TX0008812907</u>	<u>2018</u>
<u>Xospata (gilteritinib)</u>	<u>TX0008794310</u>	<u>2018</u>

<u>XPERI (FORMERLY TESSERA) v. SAMSUNG: AN INITIAL LOOK AT XPERI'S ITC LAWSUIT.</u>	<u>TX0008809494</u>	<u>2018</u>
<u>Xtandi (MDVN): Medivation's Xtandi Likely Protected From Generic Competition Until 2027.</u>	<u>TX0007947759</u>	<u>2014</u>
<u>Xyrem: An Early Look At The Xyrem Patent Situation.</u>	<u>TX0007388034</u>	<u>2010</u>
<u>Xyrem (JAZZ v. Roxane): An Introduction To The April 26 Markman Hearing And A Lawsuit Update.</u>	<u>TX0007544095</u>	<u>2012</u>
<u>Xyzal (PRGO): An Early Look at the UCB v. Synthron Lawsuit.</u>	<u>TX0007387911</u>	<u>2010</u>
<u>Yupelri (revefenacin)</u>	<u>TX0008793395</u>	<u>2018</u>
<u>Zegerid (SNTS v. PRX): Appeals Court Likely Will Remand Lawsuit Back To District Court For Reconsideration.</u>	<u>TX0007419181</u>	<u>2011</u>
<u>Zemplar: Generic Competition Possible In October 2012.</u>	<u>TX0007388035</u>	<u>2010</u>
<u>Zerenex Update (KERX): An Early Look At The Zerenex Patent Portfolio.</u>	<u>TX0007672859</u>	<u>2013</u>
<u>Zerenex update (KERX): An early look at the Zerenex patent portfolio & 99 other titles.</u>	<u>V9938D676</u>	<u>2016</u>
<u>Zetia: Merck Appears To Have Advantage Despite Possible Flaws in Patent.</u>	<u>TX0007388014</u>	<u>2010</u>
<u>ZILRETTA UPTAKE LIKELY TO REMAIN LIMITED DUE TO LACK OF CLEAR SUPERIORITY; EXPANDED INDICATIONS COULD AID FUTURE GROWTH.</u>	<u>TX0008814021</u>	<u>2018</u>
<u>Zinplava (bezlotoxumab): Reduction in recurrence of clostridium difficile infection (CDI)</u>	<u>TX0008425466</u>	<u>2017</u>
<u>Zoll Lifevest Patents Appear Likely To Exclude Competition Only Until May 2016.</u>	<u>TX0007387928</u>	<u>2011</u>
<u>Zyclara (MRX): Patent Office Set To Issue Two New Patents: Litigation Likely To Follow Quickly.</u>	<u>TX0007577417</u>	<u>2012</u>
<u>ZYTIGA (ABIRATERONE) GLOBAL INSIGHTS REPORT: EUROPEAN PATENT OFFICE TO DECIDE VALIDITY OF 2027 PATENT AT FEBRUARY 15-16 HEARING.</u>	<u>TX0008356872</u>	<u>2016</u>

<u>ZYTIGA (ABIRATERONE): UNDERSTANDING JANSSEN'S AND PROSPECTIVE ANDA FILERS? ABIRATERONE PATENTS.</u>	<u>TX0008114795</u>	<u>2015</u>
<u>ZYTIGA (JNJ): A PREVIEW OF THE COMING TRIAL.</u>	<u>TX0008814009</u>	<u>2018</u>
<u>Zytiga (JNJ, BTG): An Overview Of The Zytiga Patent Situation.</u>	<u>TX0007776998</u>	<u>2013</u>

EXHIBIT B

Patents

<u>Description</u>	<u>Application Number</u>	<u>Application Date</u>
N/A		

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial Application Number</u>	<u>Application Date</u>
IPD Analytics	90211197	Live
Budget Impact Powered by IPD Analytics	90004429	Live
IPD Analytics	88595214	Live
Market & Financial Insights Powered by IPD Analytics	88595841	Live
IPD Analytics	86118291	Live
IPDAnalytics	85535880	Live